PCT & Support

Anastrozol 1 mg Swiss Pharmaceuticals

Swiss Pharmaceuticals

35,00

In Stock (100 available)

Anastrozol 1 mg Swiss Pharmaceuticals (1 mg) — As a third-generation aromatase inhibitor, Anastrozole offers advantages over both first-generation AIs and SERMs: faster onset of…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

Anastrozol 1 mg Swiss Pharmaceuticals — As a third-generation aromatase inhibitor, Anastrozole offers advantages over both first-generation AIs and SERMs: faster onset of action, more predictable dose-response, and selective inhibition that preserves beneficial estrogenic activity in bone and cardiovascular tissue. This formulation is dosed at 1 mg per unit.

Key Benefits

  • Aromatase inhibitor — blocks oestrogen synthesis at the source
  • Standard on-cycle AI for testosterone-based protocols
  • Low dose (0.25–0.5 mg EOD) typically sufficient for 400–500 mg test
  • Dose by bloodwork — sensitive E2 assay, target 20–40 pg/mL
  • Crashing E2 feels worse than mildly elevated E2 — err on the low side
  • Each unit dosed at 1 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: 0.25–0.5 mg every other day on testosterone-based cycles. Titrate to bloodwork (sensitive E2 assay, target 20–40 pg/mL). Higher doses required only on aggressive 700+ mg/week test protocols. During PCT: not used (blocks oestrogen needed for LH signalling).

How It Works

Non-steroidal aromatase inhibitor. Binds and inactivates the aromatase enzyme (CYP19A1) that converts testosterone and androstenedione to estradiol and estrone. Reversible binding — effect disappears within days of stopping.

Potential Side Effects

Primary risk: crashed E2 — joint pain, low libido, lethargy, brain fog. If these appear, drop dose immediately. Lipid impact modest. No hepatic toxicity.

Pharmacokinetics

Plasma half-life approximately 50 hours. Every-other-day dosing produces stable serum and tissue levels. Steady-state in 7 days.

Cycle & Stacking Guide

Used on-cycle with aromatising compounds (testosterone, methandienone, oxymetholone). Start at 0.25 mg EOD, bloodwork at week 4, adjust. Never used during PCT — needed estrogen signalling for LH/FSH recovery.

Manufacturer Notes

Swiss Pharmaceuticals is a research-compound producer with published batch QC data. Vials ship with tamper-evident caps and date-coded labels.

Storage & Handling

Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Anastrozol 1 mg Swiss Pharmaceuticals”

Your email address will not be published. Required fields are marked *